Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Flare Therapeutics Inc.

Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
From Flare Therapeutics Inc.
Via GlobeNewswire
Flare Therapeutics to Present FX-909 Phase 1A Data in Oral Presentation at Upcoming AACR-NCI-EORTC International Conference
From Flare Therapeutics Inc.
Via GlobeNewswire
Flare Therapeutics to Participate in Upcoming Investor Conferences in September
From Flare Therapeutics Inc.
Via GlobeNewswire
Flare Therapeutics Announces Initiation of Phase 1B Study of FX-909 for Treatment of Metastatic Urothelial Cancer
From Flare Therapeutics Inc.
Via GlobeNewswire
Flare Therapeutics to Present Overview of Clinical Candidate FX-909 at AACR Annual Meeting
From Flare Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.